B CELL MALIGNANCIES
Clinical trials for B CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new B CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for B CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
MRNA cancer therapy takes on tough B-Cell tumors
Disease control Not yet recruitingThis early-phase trial tests a new mRNA drug called WGb-0301 in 9 patients with B-cell cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. The drug uses lipid nanoparticles to deliver mRNA that targets a protein called CD19 on cancer cells.…
Matched conditions: B CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 24, 2026 01:04 UTC
-
New CAR T-Cell therapy targets tough blood cancers
Disease control Not yet recruitingThis study tests a new treatment called SHB-02-CD19 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The study a…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Double-Pronged CAR t cells take aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check the safety …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New drug HRS-1635 enters early human testing for hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests the safety and tolerability of a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. Researchers will find the best dose and watch for side effects. The goal is to control the disease, no…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New immune clues could unlock better b-cell cancer treatments
Knowledge-focused Not yet recruitingThis study will measure two immune system markers, CD305 and CD85d, on cancer cells from 180 people newly diagnosed with B-cell blood cancers. The goal is to see how these markers relate to different cancer types and patient outcomes. No treatment is given; the study only observe…
Matched conditions: B CELL MALIGNANCIES
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:07 UTC
-
Scientists hunt for immune weak spots in B-Cell cancers
Knowledge-focused Not yet recruitingThis study looks at two immune-related proteins, CD274 and CD276, in people newly diagnosed with B-cell cancers like leukemia and lymphoma. Researchers will use a blood test to measure these proteins and see how they help cancer hide from the immune system. The goal is to find be…
Matched conditions: B CELL MALIGNANCIES
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:09 UTC